Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor +/- GVD for Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04624984Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in classical Hodgkin lymphoma (cHL), sponsored by Sun Yat-sen University. Primary endpoint: Complete Remission Rate at 2 years. Status: unknown.
02
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04624984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624984.